Thrombin alfa - ZymoGenetics

Drug Profile

Thrombin alfa - ZymoGenetics

Alternative Names: Recombinant thrombin - ZymoGenetics; Recothrom; rhThrombin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Bayer HealthCare; ZymoGenetics
  • Class Antihaemorrhagics; Blood coagulation factors; Serine endopeptidases
  • Mechanism of Action Fibrin stimulants; Serine endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 01 Feb 2016 Mallinckrodt plc acquired the haemostasis portfolio of The Medicines Company
  • 20 Apr 2015 No recent reports on development identified - Preregistration for Surgical blood loss in Australia (Topical)
  • 09 May 2013 Launched for Surgical blood loss (in children greater than or equal to 1 month of age) in USA (Topical, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top